Anton, MD, medical director at Slimz Weightloss, not involved in this research, said that this research on body weight reduction with tirzepatide is promising and aligns with our clinical observations. The findings could provide deeper insights into the efficacy of tirzepatide across different demographics, potentially allowing for more personalized treatment plans, Anton explained
If approved, commercial availability would follow, though manufacturing ramp-up could delay widespread access
Topical application protocols Not everyone wants to inject
*Featured therapies are compounded and have not been approved nor evaluated for safety, effectiveness, or quality by the FDA
It remains unclear precisely how much these developments may have affected new drug approvals during 2025
Weight loss is a significant consideration for both medications, especially given the obesity epidemic and its association with conditions like Type 2 Diabetes